Keywords: wyeth, neratinib, shows, 16-week, pfs, her2, patients

Wyeth's neratinib shows 45% 16-week PFS in HER2 patients

Article | 01 June 2009

Print This

US drug major Wyeth reported strong preliminary data from an ongoing Ph I/II study of neratinib plus Roche's Herceptin ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in